SML0613

Rofecoxib

≥98% (HPLC)

• Sinônimo(s): 4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
• Fórmula empírica (Notação de Hill): C₁₇H₁₄O₄S
• Número CAS: 162011-90-7
• Peso molecular: 314.36
• Código UNSPSC: 12352200
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• Formulário: powder
• cor: white to beige
• solubilidade: DMSO: 5 mg/mL, clear (warmed)
• temperatura de armazenamento: 2-8°C
• cadeia de caracteres SMILES: [S](=O)(=O)(C)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3
• InChI: 1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
• chave InChI: RZJQGNCSTQAWON-UHFFFAOYSA-N

Descrição

Aplicação

Rofecoxib has been used in high performance bioaffinity chromatography.

Ações bioquímicas/fisiológicas

Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with >800-fold COX-2 selectivity in CHO cells expressing human COX-1 and COX-2.

Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor.

Rofecoxib is derived from furanone and has the ability to cross human placenta. Along with anti-inflammatory action, it possesses analgesic and antipyretic properties. Cytosolic hepatic enzymes are responsible for the metabolism of rofecoxib. It is known to cause oligohydramnios and ductus arteriosus constrictions. Rofecoxib inhibits the action of CYP1A2 (cytochrome P450 family 1 subfamily A member 2). It might be associated with aseptic meningitis. Rofecoxib is known to ameliorate the risk of colorectal adenoma, but might contribute to toxicity.

Informações de segurança

• Pictogramas: GHS07
• Palavra indicadora: Warning
• Frases de perigo: H302
• Declarações de precaução: P264 - P270 - P301 + P312 - P501
• Classificações de perigo: Acute Tox. 4 Oral
• Código de classe de armazenamento: 11 - Combustible Solids
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable